The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | Advances in colorectal cancer therapies at ESMO 2023
Julien Taieb, MD, PhD, Paris Descartes University, Paris, France, outlines the results of the Phase III SUNLIGHT (NCT04737187) and FRESCO-2 (NCT04322539) trials which assessed trifluridine plus bevacizumab and fruquintinib respectively in heavily pretreated metastatic colorectal cancer. Both trials show significant increases in overall survival, with trifluridine plus bevacizumab becoming the new standard therapy, with the potential for fruquintinib as a later-line treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
